Novartis Will Resubmit COX-2 Inhibitor In The U.S. In 2007
This article was originally published in The Pink Sheet Daily
Executive Summary
Prexige is approved in EU and Canada for osteoarthritis symptoms, company announces.
You may also be interested in...
Prexige Review Will Not Include FDA Arthritis Drugs Advisory Committee
Novartis expects action later this year on lumiracoxib after resubmitting the application, the company tells “The Pink Sheet” DAILY.
Prexige Review Will Not Include FDA Arthritis Drugs Advisory Committee
Novartis expects action later this year on lumiracoxib after resubmitting the application, the company tells “The Pink Sheet” DAILY.
Novartis Bullish About Prexige; Anticipates Blockbuster Potential
Company takes a more bullish stance on its COX-2 inhibitor than Merck, which has assumed FDA approval of its Vioxx follow-on product Arcoxia in 2007.